Page 182 - Read Online

Page 8 of 8 Zheng et al. Hepatoma Res 2018;4:17 I http://dx.doi.org/10.20517/2394-5079.2018.08

67. Awe K, Lambert C, Prange R. Mammalian BiP controls posttranslational ER translocation of the hepatitis B virus large envelope
protein. FEBS Lett 2008;582:3179-84.
68. Kadowaki H, Nishitoh H, Ichijo H. Survival and apoptosis signals in ER stress: the role of protein kinases. J Chem Neuroanat
2004;28:93-100.
69. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells
from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem
2003;278:20915-24.
70. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, Harding H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D,
Wouters BG, Koumenis C. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J
2005;24:3470-81.
71. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O, Yamamoto N, Yamamoto M.
Activation of the ATF6, XBP1 and GRP78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway
in hepatocarcinogenesis. J Hepatol 2003;38:605-14.
72. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B
virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004;25:2023-32.
73. Hsieh YH, Hsu JL, Su LJ, Huang W. Genomic instability caused by hepatitis B virus: into the hepatoma inferno. Front Biosci
2011;16:2586-97.
74. Teng CF, Wu HC, Shyu WC, Jeng LB, Su LJ. Pre-S2 mutant-induced mammalian target of rapamycin signal pathways as potential
therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma. Cell Transplant 2017;26:429-38.
75. Wang LH, Huang W, Lai MD, Su LJ. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2
mutants and its implication in hepatocarcinogenesis. Carcinogenesis 2012;33:466-72.
76. Hsieh YH, Chang YY, Su IJ, Yen CJ, Liu YR, Liu RJ, Hsieh WC, Tsai HW, Wang LH, Huang W. Hepatitis B virus pre-S2 mutant
large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis. J Pathol
2015;236:337-47.
77. Hung JH, Su LJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC, Lai MD. Endoplasmic reticulum
stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase.
J Biol Chem 2004;279:46384-92.
78. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589-94.
79. Teng CF, Hsieh WC, Wu HC, Lin YJ, Tsai HW, Huang W, Su LJ. Hepatitis B virus Pre-S2 mutant induces aerobic glycolysis through
mammalian target of rapamycin signal cascade. PLoS One 2015;10:e0122373.
80. Hudu SA, Malik YA, Niazlin MT, Harmal NS, Sekawi Z. An overview of hepatitis B virus surface antigen mutant in the Asia Pacific.
Curr Issues Mol Biol 2014;16:69-78.
81. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, Gudavalli M, Krugman S. Perinatal hepatitis B virus transmission in the
United States. Prevention by passive-active immunization. JAMA 1985;253:1740-5.
82. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006;5:707-16.
83. Roggendorf M, Schulte I, Xu Y, Lu M. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model. J
Viral Hepat 2007;14:51-7.
84. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with
chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:167-78.
85. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-
related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-14.
86. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T,
Karayiannis P. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J
Hepatol 2011;55:61-8.
87. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL. Kinetics of hepatitis B surface
antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54.
88. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, Schulz S, Bock CT, Tillmann HL, Manns MP, Wedemeyer H, Cornberg M.
Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss
during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-24.
89. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49:S174-84.
90. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49:S103-11.
91. Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW, Kaufman RJ. Antioxidants reduce endoplasmic reticulum stress and
improve protein secretion. Proc Natl Acad Sci U S A 2008;105:18525-30.
92. Tsai JJ, Kuo HC, Lee KF, Tsai TH. Glycyrrhizin represses total parenteral nutrition-associated acute liver injury in rats by suppressing
endoplasmic reticulum stress. Int J Mol Sci 2013;14:12563-80.
93. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver
cirrhosis and hepatocellular carcinoma. Oncology 2002;62:94-100.